News|Articles|September 2, 2021

COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of September 2, 2021

Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

How widespread is the Delta variant (B.1.617.2) in the US?

According to early estimates from the Centers for Disease Control and Prevention (CDC), as of August 31, 2021, the SARS-CoV-2 Delta variant made up 99.1% of COVID-19 cases in the United States.

The CDC estimates as of August 31, 2021, the 5 states with the highest unweighted proportion of new cases attributed to the SARS-CoV-2 Delta variant are:

1. District of Columbia: 98.9%
2. Vermont: 98.7%
3. Kansas: 97.8%
4. Pennsylvania: 97.8%
5. Virginia: 97.4%

How many people in the US have been vaccinated against COVID-19?

According to the CDC as of today, September 2, 2021, at 2:21 PM, EDT:

• 62% of total US population has received at least 1 dose
• 52.7% of total US population is fully vaccinated

The 5 states with the highest percentage of population fully vaccinated are:

1. Vermont: 68%
2. Connecticut: 66.2%
3. Massachusetts: 66.1%
4. Maine: 66%
5. Rhode Island: 65%

How many cases of COVID-19 have been confirmed in the US?

According to the Johns Hopkins COVID-19 interactive map, as of today, September 2, 2021 at 2:21 PM, EDT, there have been:

• 39 472 426 confirmed cases and
• 642 817 deaths

The 5 states with the highest total confirmed cases are:

1. California: 4 386 298
2. Texas: 3 641 340
3. Florida: 3 223 249
4. New York: 2 284 423
5. Illinois: 1 532 346

Deaths: California has the highest number of deaths due to COVID-19 with 66 116 reported fatalities, followed by Texas with 57 407 and New York with 54 309.

How many cases of COVID-19 have been confirmed globally?

Globally, there have been 218 814 466 confirmed cases, 4 548 237 deaths, and 5 358 799 755 vaccine doses administered.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of September 2, 2021

How widespread is the Delta variant (B.1.617.2) in the US?

How many people in the US have been vaccinated against COVID-19?

How many cases of COVID-19 have been confirmed in the US?

How many cases of COVID-19 have been confirmed globally?

Newsletter

Related Content

The Adult Immunization Catch-Up Schedule: A Practical Guide for Primary Care

Undertreated Acute Pain Poses Long-Term Risks, But Prescription Opioids Still Do, Too ...

Diagnosing DVT: Clinical Pearls for Challenging Presentations

Identifying and Managing Vascular Disease in Primary Care: A Q&A With Family Physician Kabiul Haque, MD

New Menopause Survey Finds Energy Loss, Poor Sleep, and Seasonal Symptoms Most Disruptive

Latest CME

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)

Interventional Glaucoma: The Convergence of Surgical Innovation and Therapeutic Hope

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Southern Florida Psychiatry Conference

Expert Illustrations and Commentaries™: The Role of the Paracellular Pathway in the Management of Hyperphosphatemia in CKD

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Identifying and Treating CIDP in the Modern Era

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Breast Cancer Symposia in San Antonio

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology

Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Addressing Health Care Inequities™: Taking a More Mindful Approach to the Care of Every Patient Presenting With ATTR-CM

Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Real Psychiatry 2026

23rd Annual Winter Lung Cancer Conference®

EnVision Summit

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

43rd Annual Miami Breast Cancer Conference®

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)

2nd Annual Hawaii Cancer Conference

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Homing in on the Role of PSMA in Prostate Cancer – Harnessing the Power of Precision Medicine Through Imaging and Therapy to Individualize Treatment Plans

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Expert Perspectives on Technological Advances in Cataract Surgery

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials